Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca, Jubilant Biosys Join Hands For Leads In Neuroscience

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Collaborative research between Indian and multinational drug companies gained further ground as Jubilant Biosys signed an agreement with AstraZeneca for delivering novel drug candidates to strengthen its preclinical pipeline. Based out of Bangalore, Jubilant Biosys is the research arm of Jubilant Organosys

You may also be interested in...



AstraZeneca R&D VP Steve Yang On Building R&D Success In Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)

The global pharma market in the next five years is expected to grow 3-6% compared to 6.2% in the past five years, while emerging markets will drive major growth and will hold 28% of global spending on medicines by 2015.

AstraZeneca R&D VP Steve Yang On Building R&D Success In Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)

The global pharma market in the next five years is expected to grow 3-6% compared to 6.2% in the past five years, while emerging markets will drive major growth and will hold 28% of global spending on medicines by 2015.

With Too Much To Handle, Indian Pharma Companies Face Uphill Task In Their Quest To Clinch New Contracts, Grow Further

MUMBAI - Compulsions for large-scale investments, paucity of medicinal chemistry skills that can be valued from an intellectual property standpoint and pressures of sustaining multiple portfolio-based partnerships for discovering new compounds are seen as some of the biggest challenges faced by the Indian pharmaceutical industry, executives at top Indian companies told the PharmAsia Summit in San Francisco Oct. 27

Related Content

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel